

NEWS RELEASE

Viopas Venture Consulting welcomes Ulf Grawunder, PhD, and Daniel Pajer as new Managing Partners

Uster/Zürich, Switzerland, December 01, 2021 – Viopas Venture Consulting, dedicated advisor to Biotech, Pharma and Digital Health companies as well as investors in the healthcare industry with focus on Switzerland, Austria and Germany, announces today the engagement of Ulf Grawunder, PhD, and Daniel Pajer as new Managing Partners.

Managing Partners **Simon Nebel, PhD, MBA**, and **Thomas Meier, PhD**, stated: “We are very pleased to welcome Ulf and Daniel as additional Managing Partners to the team. Their expertise as successful life science entrepreneur and finance and regulatory compliance specialist, respectively, will strengthen our team, as we see increasing interest and demand from the investor community as well as from life science companies in the services provided by Viopas Venture Consulting.”

Ulf Grawunder mentioned “I am excited to join Viopas Venture Consulting as a new Managing Partner. Viopas Venture Consulting has established itself as a trusted partner to investors and stakeholders in the life science arena, providing valuable advice and decision criteria for healthcare businesses, investors and family offices. I am very much looking forward to contributing my entrepreneurial and scientific expertise to further strengthen the already excellent foundation of the team for the benefits of its current and future clients.”

Daniel Pajer added "As CFO of Viopas Venture Consulting, I am very much looking forward to contributing my long-standing expertise from serving domestic and international clients in a wide range of financial and organizational matters, including financial reporting, transformation, risk management and regulatory compliance. My background optimally complements the skill-set of our partnership and I will ensure that our services to clients and the business of Viopas Venture Consulting is managed effectively."

About Ulf Grawunder, PhD

Ulf Grawunder is a successful serial Biotech entrepreneur, who has founded and exited two Biotech companies (4-Antibody and NBE-Therapeutics) and who recently co-founded a third new venture in the area of oncology (T-CURX). In 2004, he co-founded 4-Antibody AG in Basel, where he initially served as start-up CEO and later as CSO. 4-Antibody was a therapeutic antibody discovery company, which was sold to US-based Agenus Inc. (NASDAQ: AGEN). After this, Ulf founded the oncology company NBE-Therapeutics in Basel, Switzerland, building the company as CEO and Board member

from the ground up to an internationally recognized player in the field of antibody-drug conjugates for cancer therapy. In December 2020, Boehringer Ingelheim announced the plan to acquire NBE-Therapeutics for USD 1.4 billion, which was consummated in January 2021.

Beyond his corporate roles, Ulf is advisor and teaching faculty member of several institutions, including the immune elite master studies program (Erlangen, Germany), the Swiss Venture Kick start-up program, the European Center for Pharmaceutical Medicine (Basel, Switzerland). Ulf also serves as Vice-president and Board member of the Swiss Biotech Association and, since recently, is co-founder of T-CURX, a spin-off from the University of Würzburg, Germany, active in developing CAR-T cell-based cancer therapies, where he will soon assume the role of a Board member.

A Biochemist by training, Ulf received his PhD in Immunology from the Basel Institute for Immunology. During his academic career he worked as a researcher at Washington University School of Medicine, St. Louis (USA), the University of Southern California, Los Angeles (USA), and the Basel Institute for Immunology. Ulf also holds a Diploma of Technology Entrepreneurship from the University of St. Gallen.

About Daniel Pajer

Daniel Pajer is a senior audit professional and consultant who built his expertise in finance, governance, risk management and compliance over the past 25 years. For the last 10 years, he was an Equity Partner with PwC Switzerland.

During his career, he served a wide range of clients in the financial services industry, specializing in the institutional asset management business and its global operations. Daniel's particular interest was dedicated to the financing of venture capital and the management of private markets funds. His expertise covers organizational, structuring, legal, tax and regulatory requirements of the business.

Daniel enjoys working on demanding client projects and he gained extensive leadership experience as a department head, career coach and during his two-year secondment in the PwC Network. He holds a federal diploma as a certified public accountant and is a 2022 Executive Master in Business Administration candidate.

As CFO of Viopas Venture Consulting, Daniel will also be responsible for compliance topics.

About Viopas Venture Consulting (VVC)

Viopas Venture Consulting is an advisory and consultancy boutique for the life science industry and healthcare investors with focus on Switzerland, Austria and Germany. The firm's clients are Biotech, early-stage and established Pharma and Digital Health companies seeking advice in business development, corporate strategy, M&A and financing. In addition, VVC supports and consults investors interested in the healthcare industry, including family offices, high-net worth individuals and institutional investors. VVC's managing partners Thomas Meier and Simon Nebel are also partners of Board Advisors Deutschland AG (www.boardadvisors.de).

Contacts

www.viopasventure.ch

Simon Nebel, PhD, MBA
Founder, Managing Partner, CEO
simon@viopasventure.ch

Thomas Meier, PhD
Managing Partner
thomas@viopasventure.ch

Ulf Grawunder, PhD
Managing Partner
ulf@viopasventure.ch

Daniel Pajer
Managing Partner, CFO
daniel@viopasventure.ch

###